222 related articles for article (PubMed ID: 11772242)
1. Ertapenem: a new carbapenem.
Odenholt I
Expert Opin Investig Drugs; 2001 Jun; 10(6):1157-66. PubMed ID: 11772242
[TBL] [Abstract][Full Text] [Related]
2. Sulopenem: An Intravenous and Oral Penem for the Treatment of Urinary Tract Infections Due to Multidrug-Resistant Bacteria.
Zhanel GG; Pozdirca M; Golden AR; Lawrence CK; Zelenitsky S; Berry L; Schweizer F; Bay D; Adam H; Zhanel MA; Lagacé-Wiens P; Walkty A; Irfan N; Naber K; Lynch JP; Karlowsky JA
Drugs; 2022 Apr; 82(5):533-557. PubMed ID: 35294769
[TBL] [Abstract][Full Text] [Related]
3. [Comparative in vitro activity of ertapenem against aerobic and anaerobic bacteria].
Loza E; Morosini MI; Cantón R; Almaraz F; Reig M; Baquero F
Rev Esp Quimioter; 2003 Jun; 16(2):209-15. PubMed ID: 12973459
[TBL] [Abstract][Full Text] [Related]
4. Doripenem (S-4661), a novel carbapenem: comparative activity against contemporary pathogens including bactericidal action and preliminary in vitro methods evaluations.
Jones RN; Huynh HK; Biedenbach DJ; Fritsche TR; Sader HS
J Antimicrob Chemother; 2004 Jul; 54(1):144-54. PubMed ID: 15190031
[TBL] [Abstract][Full Text] [Related]
5. In vitro evaluation of ertapenem (MK-0826), a long-acting carbapenem, tested against selected resistant strains.
Jones RN
J Chemother; 2001 Aug; 13(4):363-76. PubMed ID: 11589478
[TBL] [Abstract][Full Text] [Related]
6. In vitro activity of ertapenem: review of recent studies.
Wexler HM
J Antimicrob Chemother; 2004 Jun; 53 Suppl 2():ii11-21. PubMed ID: 15150179
[TBL] [Abstract][Full Text] [Related]
7. Bactericidal activity of ertapenem against major intra-abdominal pathogens.
Borbone S; Cascone C; Santagati M; Mezzatesta ML; Stefani S
Int J Antimicrob Agents; 2006 Nov; 28(5):396-401. PubMed ID: 17045463
[TBL] [Abstract][Full Text] [Related]
8. In-vitro activity of meropenem against clinical isolates in a multicentre study in Italy.
Schito GC; Sanna A; Chezzi C; Ravizzola G; Leone F; Molinari G; Menozzi MG; Pirali F
J Antimicrob Chemother; 1989 Sep; 24 Suppl A():57-72. PubMed ID: 2681128
[TBL] [Abstract][Full Text] [Related]
9. Comparative review of the carbapenems.
Zhanel GG; Wiebe R; Dilay L; Thomson K; Rubinstein E; Hoban DJ; Noreddin AM; Karlowsky JA
Drugs; 2007; 67(7):1027-52. PubMed ID: 17488146
[TBL] [Abstract][Full Text] [Related]
10. Pharmacodynamic modeling of carbapenems and fluoroquinolones against bacteria that produce extended-spectrum beta-lactamases.
Moczygemba LR; Frei CR; Burgess DS
Clin Ther; 2004 Nov; 26(11):1800-7. PubMed ID: 15639692
[TBL] [Abstract][Full Text] [Related]
11. [Activity of ertapenem and 19 other antimicrobial agents against beta-lactam-resistant Streptococcus pneumoniae and Haemophilus influenzae respiratory tract isolates].
Gómez-Garcés JL; Alós JI; Alhambra A; Hernáiz C
Enferm Infecc Microbiol Clin; 2005 Feb; 23(2):67-70. PubMed ID: 15743576
[TBL] [Abstract][Full Text] [Related]
12. Comparisons of parenteral broad-spectrum cephalosporins tested against bacterial isolates from pediatric patients: report from the SENTRY Antimicrobial Surveillance Program (1998-2004).
Jones RN; Sader HS; Fritsche TR; Pottumarthy S
Diagn Microbiol Infect Dis; 2007 Jan; 57(1):109-16. PubMed ID: 16930923
[TBL] [Abstract][Full Text] [Related]
13. [Investigation of the susceptibilities of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella spp. strains to ertapenem and other carbapenems].
Kuzucu C; Yetkin F; Görgeç S; Ersoy Y
Mikrobiyol Bul; 2011 Jan; 45(1):28-35. PubMed ID: 21341156
[TBL] [Abstract][Full Text] [Related]
14. Antimicrobial activity of doripenem (S-4661): a global surveillance report (2003).
Fritsche TR; Stilwell MG; Jones RN
Clin Microbiol Infect; 2005 Dec; 11(12):974-84. PubMed ID: 16307551
[TBL] [Abstract][Full Text] [Related]
15. In vitro activities of ertapenem (MK-0826) against recent clinical bacteria collected in Europe and Australia.
Livermore DM; Carter MW; Bagel S; Wiedemann B; Baquero F; Loza E; Endtz HP; van Den Braak N; Fernandes CJ; Fernandes L; Frimodt-Moller N; Rasmussen LS; Giamarellou H; Giamarellos-Bourboulis E; Jarlier V; Nguyen J; Nord CE; Struelens MJ; Nonhoff C; Turnidge J; Bell J; Zbinden R; Pfister S; Mixson L; Shungu DL
Antimicrob Agents Chemother; 2001 Jun; 45(6):1860-7. PubMed ID: 11353638
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of the in vitro activity of six broad-spectrum beta-lactam antimicrobial agents tested against over 2,000 clinical isolates from 22 medical centers in Japan. Japan Antimicrobial Resistance Study Group.
Yamaguchi K; Mathai D; Biedenbach DJ; Lewis MT; Gales AC; Jones RN
Diagn Microbiol Infect Dis; 1999 Jun; 34(2):123-34. PubMed ID: 10354863
[TBL] [Abstract][Full Text] [Related]
17. Comparative in vitro activity of ertapenem against bacterial pathogens isolated from patients with lower respiratory tract infections.
Hicks PS; Pelak B; Woods GL; Bartizal KF; Motyl M
Clin Microbiol Infect; 2002 Nov; 8(11):753-7. PubMed ID: 12445016
[TBL] [Abstract][Full Text] [Related]
18. In vitro and in vivo antibacterial activities of SM-216601, a new broad-spectrum parenteral carbapenem.
Ueda Y; Kanazawa K; Eguchi K; Takemoto K; Eriguchi Y; Sunagawa M
Antimicrob Agents Chemother; 2005 Oct; 49(10):4185-96. PubMed ID: 16189097
[TBL] [Abstract][Full Text] [Related]
19. Novel carbapenem antibiotics for parenteral and oral applications: in vitro and in vivo activities of 2-aryl carbapenems and their pharmacokinetics in laboratory animals.
Fujimoto K; Takemoto K; Hatano K; Nakai T; Terashita S; Matsumoto M; Eriguchi Y; Eguchi K; Shimizudani T; Sato K; Kanazawa K; Sunagawa M; Ueda Y
Antimicrob Agents Chemother; 2013 Feb; 57(2):697-707. PubMed ID: 23147735
[TBL] [Abstract][Full Text] [Related]
20. In vitro activities of three carbapenems against recent bacterial isolates from severely ill patients at Swedish hospitals.
Fraenkel CJ; Ullberg M; Bernander S; Ericson E; Larsson P; Rydberg J; Törnqvist E; Melhus A
Scand J Infect Dis; 2006; 38(10):853-9. PubMed ID: 17008228
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
